AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Why Rocket Lab Stock Popped 11% Today
Reports indicate that Stifel analyst Erik Rasmussen raised his estimated valuation of the New Zealand rocket-maker by more ...
Zacks.com on MSN2h
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two companies is the best option for those ...
Hosted on MSN3h
Is Viking Therapeutics a Buy on the Dip?
The biotech company presented solid data for a candidate that ... and reported favorable data from an earlier-stage oral form ...
bovnews3h
Why Is Recursion Pharmaceuticals Inc (RXRX) Stock Surpassing 8.03% from Its 50-Day SMA?
On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...
Up 41% in 1 year, I’m buying more of this growth trust for my Stocks and Shares ISA
A great performance over the last 12 months has pushed our writer to buy more of a very exciting investment trust for his Stocks and Shares ISA. Paul Summers explains why.
The Financial Times4h
AbbVie shares tumble after schizophrenia drug disappoints
The phase-two trial tested the drug on 752 patients, AbbVie added. The results are a significant blow to AbbVie, which last year spent $8.7bn buying biotech Cerevel Therapeutics to secure control of ...
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...
Rocket Lab's Neutron Rocket Drive Pushes Stock Price Target Higher to $15
Stifel ( SF, Financial) analysts have updated their price estimates, giving Rocket Lab ( RKLB, Financial) a higher value of $15 than its previous projection of $9.This update followed the Stifel 2024 ...
Without Ja Morant and multiple impact players, Memphis Grizzlies flexing early-season depth
The Memphis Grizzlies are without some of their top stars, but show they can rely on their depth, as evidenced by their blowout of the Trail Blazers.
tbsnews4h
10 firms given dividend payout deadlines, fines set for failure
Lub-rref, which raised Tk150 crore from the stock market in 2021, failed to pay the 2% cash dividend declared for FY23. The company was downgraded to the Z category by the DSE. Advent Pharma, ...
An Overview of Corvus Pharma's Earnings
Analysts estimate that Corvus Pharma will report an earnings per share (EPS) of $-0.10. The announcement from Corvus Pharma is eagerly anticipated, with investors seeking news of surpassing estimates ...